ATARA BIOTHERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.6917 USD | -3.25% |
|
-2.96% | +34.89% |
Financials (USD)
| Sales 2024 * | 98.05M | Sales 2025 * | 83.06M | Capitalization | 85.33M |
|---|---|---|---|---|---|
| Net income 2024 * | -94M | Net income 2025 * | -48M | EV / Sales 2024 * | 0.39 x |
| Net cash position 2024 * | 47.51M | Net cash position 2025 * | 57.37M | EV / Sales 2025 * | 0.34 x |
| P/E ratio 2024 * |
-0.87
x | P/E ratio 2025 * |
-2
x | Employees | 225 |
| Yield 2024 * |
289% | Yield 2025 * |
289% | Free-Float | 94.1% |
More Fundamentals
* Assessed data
More news
Latest transcript on Atara Biotherapeutics, Inc.
More recommendations
More press releases
| 1 day | -3.25% | ||
| 1 week | -2.96% | ||
| Current month | -0.33% | ||
| 1 month | +16.13% | ||
| 3 months | -5.25% | ||
| 6 months | -53.58% | ||
| Current year | +34.89% |
1 week
0.65
0.74
1 month
0.620.83
Current year
0.431.58
1 year
0.203.06
3 years
0.2020.04
5 years
0.2036.55
10 years
0.2065.56
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Touchon
CEO | Chief Executive Officer | 61 | 19-06-23 |
Eric Hyllengren
DFI | Director of Finance/CFO | - | 17-12-31 |
Anhco Nguyen
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-05-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Carol Gallagher
CHM | Chairman | 59 | 12-12-31 |
Eric Dobmeier
BRD | Director/Board Member | 55 | 15-03-25 |
William Heiden
BRD | Director/Board Member | 64 | 15-11-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 509 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 0.6917 | -3.25% | 828,693 |
| 24-04-17 | 0.7149 | +4.89% | 832,651 |
| 24-04-16 | 0.6816 | +0.44% | 1,024,577 |
| 24-04-15 | 0.6786 | -4.15% | 1,722,231 |
| 24-04-12 | 0.708 | -0.67% | 1,188,873 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Companyâs T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
0.6917
USD
Average target price
4.2
USD
Spread / Average Target
+507.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +34.89% | 85.33M | |
| -3.30% | 102B | |
| +1.79% | 96.84B | |
| -0.44% | 21.48B | |
| -18.35% | 20.82B | |
| -7.45% | 18.6B | |
| -40.31% | 16.81B | |
| -26.84% | 13.78B | |
| +0.59% | 13.4B | |
| +20.86% | 11.06B |
- Stock Market
- Equities
- ATRA Stock
